You just read:

Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients

News provided by

Viriom, Inc.

May 04, 2020, 06:15 ET